• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Affimed N.V. (Amendment)

    2/13/24 1:20:05 PM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AFMD alert in real time by email
    SC 13G/A 1 afmda2_21424.htm 683 CAPITAL MANAGEMENT, LLC afmda2_21424.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
    Affimed N.V.
    (Name of Issuer)
    Common Shares, nominal value 0.01 per share
    (Title of Class of Securities)
    N01045108
    (CUSIP Number)
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [   ] Rule 13d-1(b)
    [X] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: N01045108
           
    1
    NAME OF REPORTING PERSON
    683 Capital Management, LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    7,106,250 *
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    7,106,250 *
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    7,106,250 *
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    4.8%
    12
    TYPE OF REPORTING PERSON
    IA
    * Including warrants to purchase 106,250 Common Shares.
    CUSIP No.: N01045108
           
    1
    NAME OF REPORTING PERSON
    683 Capital Partners, LP
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    7,106,250 *
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    7,106,250 *
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    7,106,250 *
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    4.8%
    12
    TYPE OF REPORTING PERSON
    PN
    * Including warrants to purchase 106,250 Common Shares.
    CUSIP No.: N01045108
           
    1
    NAME OF REPORTING PERSON
    Ari Zweiman
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    United States of America
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    7,106,250 *
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    7,106,250 *
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    7,106,250 *
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    4.8%
    12
    TYPE OF REPORTING PERSON
    IN
    * Including warrants to purchase 106,250 Common Shares.
    CUSIP No.: N01045108
    ITEM 1(a). NAME OF ISSUER:
    Affimed N.V.
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    Im Neuenheimer Feld 582, 69120 Heidelberg, Germany.
    ITEM 2(a). NAME OF PERSON FILING:
    683 Capital Management, LLC
    683 Capital Partners, LP
    Ari Zweiman
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    The principal business address for each of the Reporting Persons is 1700 Broadway, Suite 4200, New York, NY 10019.
    ITEM 2(c). CITIZENSHIP:
    683 Capital Management, LLC is a Delaware limited liability company. 683 Capital Partners, LP is a Delaware limited partnership. Ari Zweiman is a citizen of the United States.
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Common Shares, nominal value 0.01 per share (the Common Shares)
    ITEM 2(e). CUSIP NUMBER:
    N01045108
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [ ]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    As of December 31, 2023, 683 Capital Partners, LP beneficially owned 7,106,250 Common Shares, which includes 106,250 Common Shares issuable upon the exercise of outstanding warrants.

    683 Capital Management, LLC, as the investment manager of 683 Capital Partners, LP, may be deemed to have beneficially owned the 7,106,250 Common Shares beneficially owned by 683 Capital Partners, LP.
    Ari Zweiman, as the Managing Member of 683 Capital Management, LLC, may be deemed to have beneficially owned the 7,106,250 Common Shares beneficially owned by 683 Capital Management, LLC.
    (b) Percent of class:
    The following percentage is based on 149,339,335 Common Shares outstanding as of December 31, 2022, as disclosed in the Issuers 424B5 (Prospectus) filed on March 23, 2023, plus 106,250 shares issuable upon the exercise of outstanding warrants that are freely exercisable within 60 days.

    As of December 31, 2023, the Reporting Persons may be deemed to have beneficially owned approximately 4.8% of the outstanding Common Shares.
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    See Cover Pages Items 5-9.
    (ii) shared power to vote or to direct the vote:
    See Cover Pages Items 5-9.
    (iii) sole power to dispose or direct the disposition of:
    See Cover Pages Items 5-9.
    (iv) shared power to dispose or to direct the disposition of:
    See Cover Pages Items 5-9.
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    Not applicable.
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    Not applicable.
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    See Exhibit A to Schedule 13G filed on February 7, 2022.
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    Not applicable.
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: N01045108
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 14 2024
    683 Capital Management, LLC
    By:
    /s/ Ari Zweiman
    Name:
    Ari Zweiman
    Title:
    Managing Member
    February 14 2024
    683 Capital Partners, LP
    By:
    /s/Ari Zweiman
    Name:
    Ari Zweiman
    Title:
    Authorized Person
    February 14 2024
    Ari Zweiman
    By:
    /s/Ari Zweiman
    Name:
    Ari Zweiman
    Title:
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $AFMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AFMD

    DatePrice TargetRatingAnalyst
    12/12/2022$6.00Buy
    H.C. Wainwright
    10/10/2022$9.00 → $2.00Buy → Hold
    Stifel
    8/18/2022Overweight
    Wells Fargo
    3/31/2022$7.00Overweight
    Piper Sandler
    2/23/2022$12.00Overweight
    Cantor Fitzgerald
    10/21/2021$10.00Buy
    Truist
    10/12/2021$13.00 → $12.00Outperform
    SVB Leerink
    9/30/2021$12.00Buy
    Stifel
    More analyst ratings

    $AFMD
    Financials

    Live finance-specific insights

    See more
    • Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

      MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST / 14:30 CET to review clinical data from AFM24-102, the combination trial of its AFM24 innate cell engager ICE® with atezolizumab in non-small cell lung cancer. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/in

      12/9/24 6:30:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Reports Third Quarter 2024 Financial Results & Business Update

      AFM24 combination with atezolizumab: The non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort completed enrollment: Objective response rate (ORR) and safety data to be presented on a Company conference call on December 17, 2024.Acimtamig (AFM13) combination with AlloNK® (AB-101): Updated clinical data from the four cohorts of the run-in phase to be presented in a poster session at ASH 2024.AFM28 monotherapy phase 1 dose-escalation study: Updated clinical data to be presented at an oral presentation at ASH 2024.Cash runway into Q4 2025: As of September 30, 2024, cash, cash equivalents and investments were €24.1 million. Based on operating and financial plans cash-runway projected

      11/14/24 6:30:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024

      MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2024 results and corporate update on Thursday, November 14, 2024. The Company will host a conference call at 8:30 a.m. EST / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link https://r

      11/6/24 6:30:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    SEC Filings

    See more
    • SEC Form NT 20-F filed by Affimed N.V.

      NT 20-F - Affimed N.V. (0001608390) (Filer)

      5/1/25 4:05:20 PM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Affimed N.V.

      6-K - Affimed N.V. (0001608390) (Filer)

      4/21/25 8:32:58 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Affimed N.V.

      SCHEDULE 13G/A - Affimed N.V. (0001608390) (Subject)

      2/14/25 8:18:09 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

      An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improved objective response rate (33.3% vs 5.6%) and longer progression free survival (PFS) (7.3 mo. vs 2.9 mo.) without a negative impact on safetyThese findings will be incorporated in future AFM24 trials to further improve efficacy outcomes of patients treated with AFM24 MANNHEIM, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an ex

      4/29/25 10:00:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting

      MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on the phase 2 LuminICE-203 study of its innate cell engager (ICE®) acimtamig in combination with AlloNK® (AB-101) has been accepted for an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) taking place May 30 – June 3, 2025 in Chicago, Illinois. In addition, two abstracts on AFM24 in combination with atezolizumab in non-small cell lung cancer (NSCLC) have been accepted as poster presentations. Det

      4/23/25 10:05:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

      MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the "Notice"), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the last thirty (30) consecutive business days, the bid price for the Company's common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule"). In accordance with Nasdaq Listing Rule 5810(c)(3

      4/21/25 6:30:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Affimed Appoints Shawn M. Leland as Chief Executive Officer

      MANNHEIM, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that Shawn M. Leland, PharmD, RPh has been appointed as Chief Executive Officer (CEO). Dr. Andreas Harstrick, who has been serving as acting CEO since January 2024 will continue in his position as Chief Medical Officer (CMO). Shawn is an accomplished pharmaceutical and biotechnology professional with more than 15 years of experience in the industry. He has a proven track record in successfully advancing the development of novel oncology assets, rais

      9/3/24 7:45:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board

      HEIDELBERG, Germany, June 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Dr. Constanze Ulmer-Eilfort to its Supervisory Board. Dr. Ulmer-Eilfort's appointment was approved during the Annual General Meeting of Shareholders which took place on June 21, 2023. "We are delighted to announce the appointment of Dr. Ulmer-Eilfort to our Supervisory Board," said Dr. Thomas Hecht, Chairman of Affimed's Supervisory Board. "Constanze brings a wealth of legal expertise and a deep understanding of the biotech and he

      6/22/23 6:30:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Announces Appointment of Uta Kemmerich-Keil to its Supervisory Board

      HEIDELBERG, Germany, June 16, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Ms. Uta Kemmerich-Keil as director on its Supervisory Board effective immediately. The appointment was approved during the Annual General Meeting of Shareholders on June 15, 2021. "We are pleased to welcome Uta to Affimed's Supervisory Board," said Dr. Thomas Hecht, Chairman of the Supervisory Board. "Uta brings unique and very deep and extensive executive experience in the life sciences industry. With over 20 years of leadership roles in driving higher busine

      6/16/21 7:04:39 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Affimed Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Affimed Therapeutics with a rating of Buy and set a new price target of $6.00

      12/12/22 7:32:36 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Therapeutics downgraded by Stifel with a new price target

      Stifel downgraded Affimed Therapeutics from Buy to Hold and set a new price target of $2.00 from $9.00 previously

      10/10/22 7:08:28 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo resumed coverage on Affimed Therapeutics

      Wells Fargo resumed coverage of Affimed Therapeutics with a rating of Overweight

      8/18/22 10:27:27 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Affimed N.V.

      SC 13G - Affimed N.V. (0001608390) (Subject)

      10/24/24 2:49:52 PM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Affimed N.V. (Amendment)

      SC 13G/A - Affimed N.V. (0001608390) (Subject)

      2/14/24 4:07:21 PM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Affimed N.V. (Amendment)

      SC 13G/A - Affimed N.V. (0001608390) (Subject)

      2/13/24 1:20:05 PM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care